Welcome to our dedicated page for Parabilis Medicines news (Ticker: PBLS), a resource for investors and traders seeking the latest updates and insights on Parabilis Medicines stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Parabilis Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Parabilis Medicines's position in the market.
Parabilis Medicines (Nasdaq: PBLS) priced an upsized IPO of 33,500,000 shares at $20.00 per share, targeting $670 million in gross proceeds. Underwriters hold a 30-day option for 5,025,000 additional shares.
Trading on the Nasdaq Global Select Market is expected to start June 10, 2026. Parabilis also agreed to a concurrent private placement of 4,166,666 shares at $18.00 per share to Regeneron, for about $75 million in additional proceeds. Both offerings are expected to close around June 11, 2026, subject to customary conditions.